SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pellkofer, H.
Right arrow Articles by Kuempfel, T
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pellkofer, H.
Right arrow Articles by Kuempfel, T
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

case-report

Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab

HL Pellkofer

Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Munich, Germany hannah.pellkofer{at}med.uni-muenchen.de

C Suessmair

Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Munich, Germany

A Schulze

Division of Neonatology, Dr von Hauner Children's Hospital, Ludwig Maximilians University, Munich, Germany

R Hohlfeld

Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Munich, Germany

T Kuempfel

Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Munich, Germany

In neuromyelitis optica (NMO), the monoclonal B-cell antibody rituximab is a therapeutic option. Little is known about the course of NMO and the safety of rituximab during pregnancy. In this study, we report the clinical course of a patient with NMO after application of rituximab 1 week before inadvertent conception. Mother and child did not experience any adverse event, and the postpartum development of the baby was completely normal up to 15 months. Clinical course of NMO was stable during the entire pregnancy. This case illustrates a favorable outcome in a pregnant NMO patient and her child after therapy with rituximab.

Key Words: devic’s disease • neuromyelitis • optica • pregnancy • rituximab

Multiple Sclerosis, Vol. 15, No. 8, 1006-1008 (2009)
DOI: 10.1177/1352458509106512
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement